PR Newswire Asia's news > Biotechnology

 |   Title only   |   Print    Next page > 
     
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China , July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability ...
2025-07-04T    Biotechnology   Environmental Products & Services   Health Care/Hospital   Medical/Pharmaceuticals 
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
SHANGHAI , July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative ...
2025-07-04T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...
2025-07-04T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
JILIN, China , July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer ...
2025-07-03T    Banking/Financial Service   Biotechnology   Health Care/Hospital 
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON , July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii , PhD, MBA, ...
2025-07-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement
BEIJING , July 3, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting ...
2025-07-03T    Banking/Financial Service   Biotechnology   Cosmetics & Personal Care   Internet Technology 
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
HONG KONG , July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical ...
2025-07-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size ...
2025-07-03T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
ZEGFROVY is the only  approved  targeted oral treatment  for  NSCLC  with EGFR   exon20 ins A pproval follows the U.S. FDA's Priority Review and is supported ...
2025-07-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: ...
2025-07-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.